Oncotarget, 05 July 2016, Vol.7(27), pp.41959-41973
The classification of bronchopulmonary neuroendocrine neoplasms (BP-NEN) into four tumor entities (typical carcinoids (TC), atypical carcinoids (AC), small cell lung cancers (SCLC), large cell neuroendocrine lung carcinomas (LCNEC)) is difficult to perform accurately, but important for prognostic statements and therapeutic management decisions. In this regard, we compared the expression of three proliferation markers, Ki-67, Topoisomerase II alpha (TOP2A), and RacGAP1, in a series of tumor samples from 104 BP-NEN patients (24 TC, 21 AC, 52 SCLC, 7 LCNEC) using different evaluation methods (immunohistochemistry (IHC): Average evaluation, Hotspot evaluation, digital image analysis; RT-qPCR).The results indicated that all three markers had increased protein and mRNA expression with poorer differentiation and correlated well with each other, as well as with grading, staging, and poor survival. Compared with Ki-67 and TOP2A, RacGAP1 allowed for a clearer prognostic statement. The cut-off limits...
Ihc/Rt-Qpcr ; Ki-67 ; Racgap1 ; Lung Neuroendocrine Neoplasms ; Topoisomerase 2 Alpha ; Biomarkers, Tumor -- Metabolism ; DNA Topoisomerases, Type II -- Metabolism ; Gtpase-Activating Proteins -- Metabolism ; Ki-67 Antigen -- Metabolism ; Lung Neoplasms -- Metabolism ; Neuroendocrine Tumors -- Metabolism ; Poly-Adp-Ribose Binding Proteins -- Metabolism
Permalink to record
View this record in MEDLINE/PubMed